Skip to main content
Erschienen in:

07.08.2024 | Hepatobiliary-Pancreas

An imaging-based model to predict the malignant potential of intraductal papillary mucinous neoplasm of the pancreas

verfasst von: Junghoan Park, Jung Hoon Kim, Jae Seok Bae, Hyo-Jin Kang, Seo-Youn Choi

Erschienen in: European Radiology | Ausgabe 2/2025

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To develop and validate imaging-based models for predicting the malignancy risk of intraductal papillary mucinous neoplasm (IPMN).

Materials and methods

We retrospectively analyzed data from 241 IPMN patients who underwent preoperative CT and MRI for model development. Cyst size, presence and size of the enhancing mural nodule (EMN), main pancreatic duct (MPD) diameter, thickened/enhancing cyst wall, abrupt MPD caliber change with distal atrophy, and lymphadenopathy were assessed. Multiple logistic regression models predicting malignancy risk were created using either continuous (Model C) or dichotomized variables (Model D) using these imaging features. Validation included internal (n = 55) and external (n = 43) datasets. Model performance was assessed using the area under the receiver operating characteristic curve (AUC) and compared with that of the international guideline-based model (Model F).

Results

Model C identified age, EMN size, MPD diameter, and lymphadenopathy as independent predictors on CT, and age and presence and size of EMN on MRI. Model D identified age ≥ 68, cyst size ≥ 31 mm, EMN ≥ 6 mm, MPD ≥ 7 mm, and lymphadenopathy as independent predictors on CT, and age ≥ 68, EMN ≥ 4.5 mm, and lymphadenopathy on MRI. Model C (AUC, 0.763–0.899) performed slightly better than Model D (AUC, 0.753–0.912) without statistical significance. No significant difference was observed between Models C and F (AUC, 0.729–0.952). Combining Model C with obstructive jaundice improved performance (AUC, 0.802–0.941) without statistical significance.

Conclusion

Our imaging-based models effectively predicted the malignancy risk of IPMNs, comparable to international consensus guidelines.

Clinical relevance statement

Imaging features are important for predicting the malignant potential of IPMNs. Our imaging-based model may help determine surgical candidacy for patients with IPMNs.

Key Points

  • Non-invasively determining the malignant potential of intraductal papillary mucinous neoplasms (IPMNs) allows for appropriate treatment decision-making
  • We identified multiple imaging features that are associated with malignant transformation and developed models for this prediction.
  • Our model performs comparably with international consensus guidelines in predicting the malignant potential of IPMNs.

Graphical Abstract

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Fonseca AL, Kirkwood K, Kim MP, Maitra A, Koay EJ (2018) Intraductal papillary mucinous neoplasms of the pancreas: current understanding and future directions for stratification of malignancy risk. Pancreas 47:272–279CrossRefPubMedPubMedCentral Fonseca AL, Kirkwood K, Kim MP, Maitra A, Koay EJ (2018) Intraductal papillary mucinous neoplasms of the pancreas: current understanding and future directions for stratification of malignancy risk. Pancreas 47:272–279CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Tanaka M, Fernández-del Castillo C, Kamisawa T et al (2017) Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17:738–753CrossRefPubMed Tanaka M, Fernández-del Castillo C, Kamisawa T et al (2017) Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17:738–753CrossRefPubMed
3.
Zurück zum Zitat Sahani DV, Kadavigere R, Blake M, Fernandez-del Castillo C, Lauwers GY, Hahn PF (2006) Intraductal papillary mucinous neoplasm of pancreas: multi–detector row CT with 2D curved reformations—correlation with MRCP. Radiology 238:560–569CrossRefPubMed Sahani DV, Kadavigere R, Blake M, Fernandez-del Castillo C, Lauwers GY, Hahn PF (2006) Intraductal papillary mucinous neoplasm of pancreas: multi–detector row CT with 2D curved reformations—correlation with MRCP. Radiology 238:560–569CrossRefPubMed
4.
Zurück zum Zitat Ogawa H, Itoh S, Ikeda M, Suzuki K, Naganawa S (2008) Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT. Radiology 248:876–886CrossRefPubMed Ogawa H, Itoh S, Ikeda M, Suzuki K, Naganawa S (2008) Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT. Radiology 248:876–886CrossRefPubMed
5.
Zurück zum Zitat Hwang DW, Jang J-Y, Lee SE, Lim C-S, Lee KU, Kim S-W (2012) Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution. Langenbecks Arch Surg 397:93–102CrossRefPubMed Hwang DW, Jang J-Y, Lee SE, Lim C-S, Lee KU, Kim S-W (2012) Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution. Langenbecks Arch Surg 397:93–102CrossRefPubMed
6.
Zurück zum Zitat Kim TH, Song TJ, Hwang J-H et al (2015) Predictors of malignancy in pure branch duct type intraductal papillary mucinous neoplasm of the pancreas: a nationwide multicenter study. Pancreatology 15:405–410CrossRefPubMed Kim TH, Song TJ, Hwang J-H et al (2015) Predictors of malignancy in pure branch duct type intraductal papillary mucinous neoplasm of the pancreas: a nationwide multicenter study. Pancreatology 15:405–410CrossRefPubMed
7.
Zurück zum Zitat Ohtsuka T, Fernandez-del Castillo C, Furukawa T et al (2024) International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology 24:255–270 Ohtsuka T, Fernandez-del Castillo C, Furukawa T et al (2024) International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology 24:255–270
8.
Zurück zum Zitat Hirono S, Tani M, Kawai M et al (2012) The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 255:517–522CrossRefPubMed Hirono S, Tani M, Kawai M et al (2012) The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 255:517–522CrossRefPubMed
9.
Zurück zum Zitat Shimizu Y, Yamaue H, Maguchi H et al (2013) Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers. Pancreas 42:883–888CrossRefPubMed Shimizu Y, Yamaue H, Maguchi H et al (2013) Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers. Pancreas 42:883–888CrossRefPubMed
10.
Zurück zum Zitat Kobayashi G, Fujita N, Maguchi H et al (2014) Natural history of branch duct intraductal papillary mucinous neoplasm with mural nodules: a Japan Pancreas Society multicenter study. Pancreas 43:532–538CrossRefPubMedPubMedCentral Kobayashi G, Fujita N, Maguchi H et al (2014) Natural history of branch duct intraductal papillary mucinous neoplasm with mural nodules: a Japan Pancreas Society multicenter study. Pancreas 43:532–538CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Hackert T, Fritz S, Klauss M et al (2015) Main-duct intraductal papillary mucinous neoplasm: high cancer risk in duct diameter of 5 to 9 mm. Ann Surg 262:875–880CrossRefPubMed Hackert T, Fritz S, Klauss M et al (2015) Main-duct intraductal papillary mucinous neoplasm: high cancer risk in duct diameter of 5 to 9 mm. Ann Surg 262:875–880CrossRefPubMed
12.
Zurück zum Zitat Zhao W, Liu S, Cong L, Zhao Y (2022) Imaging features for predicting high-grade dysplasia or malignancy in branch duct type intraductal papillary mucinous neoplasm of the pancreas: a systematic review and meta-analysis. Ann Surg Oncol 29:1297–1312CrossRefPubMed Zhao W, Liu S, Cong L, Zhao Y (2022) Imaging features for predicting high-grade dysplasia or malignancy in branch duct type intraductal papillary mucinous neoplasm of the pancreas: a systematic review and meta-analysis. Ann Surg Oncol 29:1297–1312CrossRefPubMed
13.
Zurück zum Zitat Nagtegaal ID, Odze RD, Klimstra D et al (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76:182–188CrossRefPubMed Nagtegaal ID, Odze RD, Klimstra D et al (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76:182–188CrossRefPubMed
15.
Zurück zum Zitat Lee JE, Choi S-Y, Min JH et al (2019) Determining malignant potential of intraductal papillary mucinous neoplasm of the pancreas: CT versus MRI by using revised 2017 international consensus guidelines. Radiology 293:134–143CrossRefPubMed Lee JE, Choi S-Y, Min JH et al (2019) Determining malignant potential of intraductal papillary mucinous neoplasm of the pancreas: CT versus MRI by using revised 2017 international consensus guidelines. Radiology 293:134–143CrossRefPubMed
16.
Zurück zum Zitat Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15:155–163CrossRefPubMedPubMedCentral Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15:155–163CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Hirono S, Kawai M, Okada K-I et al (2017) Factors associated with invasive intraductal papillary mucinous carcinoma of the pancreas. JAMA Surg 152:e165054CrossRefPubMed Hirono S, Kawai M, Okada K-I et al (2017) Factors associated with invasive intraductal papillary mucinous carcinoma of the pancreas. JAMA Surg 152:e165054CrossRefPubMed
18.
Zurück zum Zitat Hwang JA, Choi S-Y, Lee JE et al (2020) Pre-operative nomogram predicting malignant potential in the patients with intraductal papillary mucinous neoplasm of the pancreas: focused on imaging features based on revised international guideline. Eur Radiol 30:3711–3722CrossRefPubMed Hwang JA, Choi S-Y, Lee JE et al (2020) Pre-operative nomogram predicting malignant potential in the patients with intraductal papillary mucinous neoplasm of the pancreas: focused on imaging features based on revised international guideline. Eur Radiol 30:3711–3722CrossRefPubMed
19.
Zurück zum Zitat Hong SB, Lee NK, Kim S et al (2022) Diagnostic performance of magnetic resonance image for malignant intraductal papillary mucinous neoplasms: the importance of size of enhancing mural nodule within cyst. Jpn J Radiol 40:1282–1289CrossRefPubMed Hong SB, Lee NK, Kim S et al (2022) Diagnostic performance of magnetic resonance image for malignant intraductal papillary mucinous neoplasms: the importance of size of enhancing mural nodule within cyst. Jpn J Radiol 40:1282–1289CrossRefPubMed
20.
Zurück zum Zitat Kang MJ, Jang J-Y, Lee S, Park T, Lee SY, Kim S-W (2015) Clinicopathological meaning of size of main-duct dilatation in intraductal papillary mucinous neoplasm of pancreas: proposal of a simplified morphological classification based on the investigation on the size of main pancreatic duct. World J Surg 39:2006–2013CrossRefPubMed Kang MJ, Jang J-Y, Lee S, Park T, Lee SY, Kim S-W (2015) Clinicopathological meaning of size of main-duct dilatation in intraductal papillary mucinous neoplasm of pancreas: proposal of a simplified morphological classification based on the investigation on the size of main pancreatic duct. World J Surg 39:2006–2013CrossRefPubMed
21.
Zurück zum Zitat Sugimoto M, Elliott IA, Nguyen AH et al (2017) Assessment of a revised management strategy for patients with intraductal papillary mucinous neoplasms involving the main pancreatic duct. JAMA Surg 152:e163349CrossRefPubMed Sugimoto M, Elliott IA, Nguyen AH et al (2017) Assessment of a revised management strategy for patients with intraductal papillary mucinous neoplasms involving the main pancreatic duct. JAMA Surg 152:e163349CrossRefPubMed
22.
Zurück zum Zitat Zhang H, Cao Y, Ren S et al (2023) Threshold of main pancreatic duct diameter in identifying malignant intraductal papillary mucinous neoplasm by magnetic resonance imaging. Technol Cancer Res Treat 22:15330338231170942CrossRefPubMedPubMedCentral Zhang H, Cao Y, Ren S et al (2023) Threshold of main pancreatic duct diameter in identifying malignant intraductal papillary mucinous neoplasm by magnetic resonance imaging. Technol Cancer Res Treat 22:15330338231170942CrossRefPubMedPubMedCentral
Metadaten
Titel
An imaging-based model to predict the malignant potential of intraductal papillary mucinous neoplasm of the pancreas
verfasst von
Junghoan Park
Jung Hoon Kim
Jae Seok Bae
Hyo-Jin Kang
Seo-Youn Choi
Publikationsdatum
07.08.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 2/2025
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-024-11003-z

Neu im Fachgebiet Radiologie

Ringen um den richtigen Umgang mit Zufallsbefunden

Wenn 2026 in Deutschland das Lungenkrebsscreening mittels Low-Dose-Computertomografie (LDCT) eingeführt wird, wird es auch viele Zufallsbefunde ans Licht bringen. Das birgt Chancen und Risiken.

Bald 5% der Krebserkrankungen durch CT verursacht

Die jährlich rund 93 Millionen CTs in den USA könnten künftig zu über 100.000 zusätzlichen Krebserkrankungen führen, geht aus einer Modellrechnung hervor. Damit würde eine von 20 Krebserkrankungen auf die ionisierende Strahlung bei CT-Untersuchungen zurückgehen.

Röntgen-Thorax oder LDCT fürs Lungenscreening nach HNSCC?

Personen, die an einem Plattenepithelkarzinom im Kopf-Hals-Bereich erkrankt sind, haben ein erhöhtes Risiko für Metastasen oder zweite Primärmalignome der Lunge. Eine Studie hat untersucht, wie die radiologische Überwachung aussehen sollte.

Statine: Was der G-BA-Beschluss für Praxen bedeutet

Nach dem G-BA-Beschluss zur erweiterten Verordnungsfähigkeit von Lipidsenkern rechnet die DEGAM mit 200 bis 300 neuen Dauerpatienten pro Praxis. Im Interview erläutert Präsidiumsmitglied Erika Baum, wie Hausärztinnen und Hausärzte am besten vorgehen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.